Patent expiry and biosimilars: difference between revisions
Diff·revision 11 → 12·12:30, 11 May 2025
Difference between revision 11 and revision 12 of Patent expiry and biosimilars. This revision changed no lines of source — the edit was a null or whitespace change.
| Revision 11 — 17:01, 20 Apr 2025 BiosimilarBoaz (talk) attribute the compounding statement to the pharmacy board that issued it 3,580 bytes +369 | Revision 12 — 12:30, 11 May 2025 StyleSheetSybil (talk) rm the speculation about future scheduling 3,580 bytes ±0 | ||
|---|---|---|---|
| — | No change to the page source. | — |